4 min read
Milestone Monday: The Starting Gun Is Not The Finish Line
Biopharma’s US IPO class of 2026 has reached 26 and raised $8.19bn, but offerings are shrinking and many new listings have slipped below their IPO prices. Iovance shows what a strong run looks like, while the year’s biggest decliners show who hit the wall.
